These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32672965)

  • 1. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
    Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
    Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
    J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.
    Amano M; Miguel Salcedo-Gómez P; Yedidi RS; Delino NS; Nakata H; Venkateswara Rao K; Ghosh AK; Mitsuya H
    Sci Rep; 2017 Sep; 7(1):12235. PubMed ID: 28947797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
    Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
    J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
    Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
    J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
    Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
    Hohlfeld K; Wegner JK; Kesteleyn B; Linclau B; Unge J
    J Med Chem; 2015 May; 58(9):4029-38. PubMed ID: 25897791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR
    Agniswamy J; Kneller DW; Ghosh AK; Weber IT
    Biochem Biophys Res Commun; 2021 Aug; 566():30-35. PubMed ID: 34111669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.